The latest update is out from Enveric Biosciences (ENVB).
Enveric Biosciences, Inc. has announced its intention to out-license three different classes of compounds, as detailed in a recent press release. This strategic move signals the company’s ambition to leverage its intellectual property to create new partnerships and revenue streams. While the agreements are not yet binding, this development could be significant for Enveric and potential investors, as it marks a potential expansion of the company’s market presence.
Learn more about ENVB stock on TipRanks’ Stock Analysis page.
